




RealRate

PHARMACEUTICAL 2020

Aimmune Therapeutics Inc
Rank 268 of 363



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2020

Aimmune Therapeutics Inc Rank 268 of 363

The relative strengths and weaknesses of Aimmune Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aimmune Therapeutics Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 1.7% points. The greatest weakness of Aimmune Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 97% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	149,077
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,448
Liabilities, Non-Current	52,897
Other Assets	26,688
Other Compr. Net Income	188
Other Expenses	5,632
Other Liabilities	0
Other Net Income	6,939
Other Revenues	0
Property and Equipment	28,604
Research and Development	123,987
Selling, General and Administrative Expense	125,817

Output Variable	Value in 1000 USD
Assets	204,369
Liabilities	100,345
Expenses	255,436
Revenues	0
Stockholders Equity	104,024
Net Income	-248,497
Comprehensive Net Income	-248,403
BaseVar	283,638
ECR before LimitedLiability	-14%
Economic Capital Ratio	141%